Physician profile
Amit Tailor
NPI 1861431041
$5,900.83
in general payments reported to CMS, 2019-2025
34 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $375 · 2021: $847 · 2022: $867 · 2023: $1,069 · 2024: $1,131 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,598.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $983.76 | 2021-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $556.05 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Idorsia Pharmaceuticals US INC | $545.31 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $426.16 | 2019-2025 | Fasenra, Airsupra |
| Abbvie INC. | $386.08 | 2019-2025 | Qulipta, Linzess, Creon |
| Kowa Pharmaceuticals America, INC. | $327.84 | 2019-2023 | Livalo, Seglentis |
| Pfizer INC. | $327.32 | 2020-2025 | |
| Boston Scientific Corporation | $248.18 | 2021-2023 | Watchman Access System |
| Novo Nordisk INC | $201.68 | 2020-2024 | Ozempic, Rybelsus |
| Collegium Pharmaceutical, INC. | $179.07 | 2021-2025 | Xtampza |
| Xeris Pharmaceuticals, INC. | $176.16 | 2024-2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $170.61 | 2022 | |
| Medtronic, INC. | $164.82 | 2023 | Hawkone |
| Exact Sciences Corporation | $153.88 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bard Peripheral Vascular, INC. | $124.99 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $124.65 | 2024-2025 | Loreev Xr |
| Lilly USA, LLC | $123.77 | 2020-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $86.48 | 2019-2022 | |
| Glaxosmithkline, LLC. | $70.82 | 2020-2024 | Trelegy Ellipta |
| Amgen INC. | $65.11 | 2019-2021 | |
| Abbott Laboratories | $64.48 | 2021-2024 | Eterna, Proclaim |
| Neurocrine Biosciences, INC. | $58.14 | 2021-2022 | |
| Protega Pharmaceutials INC | $48.11 | 2023-2025 | Roxybond |
| Amarin Pharma, INC. | $46.45 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $39.24 | 2021 | |
| Allergan, INC. | $38.78 | 2020 | |
| Astellas Pharma US INC | $33.21 | 2021-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $29.20 | 2020 | |
| Scilex Pharmaceuticals INC. | $24.52 | 2021-2022 | |
| Smith+Nephew, INC. | $20.49 | 2025 | Collagenase Santyl |
| Sanofi-Aventis U.S. LLC | $15.00 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $14.60 | 2021 | |
| Seqirus USA INC | $13.30 | 2019 | |
| Nabriva Therapeutics, Plc | $12.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Tailor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.